Following my earlier post on this issue, it is now reported that the Indian Patent Office (IPO) has refused patent to the anti-cancer drug, Abraxane. I am yet to obtain a copy of this IPO order.
A recap
Briefly, the opposition against the patent application for Abraxane was filed by Natco Pharma with the IPO and was decided against the patent applicant, Abraxis Biosciences (“Abraxis”). Abraxis appealed against the IPO’s order with the Intellectual Property Appellate Board (IPAB) owing to certain procedural lapses. IPAB agreed with Abraxis and asked the IPO to consider the opposition afresh.
What’s new?
The recent order of the IPO is said to have stated the following:
“The amended claims (here Abraxis Boisciences) lack inventive step and do not constitute an invention under the Patents Act, 1970.”
I will update this post and discuss the IPO’s order in detail once I peruse the order.
Raja Selvam
Founder & Managing Attorney, Selvam & Selvam | Practice areas include Trademarks, Patents, Domain names & Business law. Visiting faculty, Department of Journalism, Madras University where I teach copyrights & trademarks law. Passionate about entrepreneurship, start-ups, stocks, farming, technology and law.
No Removal of Registered Mark for Non-Renewal Without Notice; Delhi HC Rules… Yet Again
Justice Midha, in his order dated May 28, 2019, reiterated the mandatory nature of Section 25(3) of the Trademarks Act, 1999. As we have noted…
There is more to your liquor than you know
The liquor bottles are often so exquisitely designed that you would want to buy it just out of admiration for its design.
Radio Sa Ga – Record Label fined for Anti-Competitive practices in Licensing Music
The Competition Commission of India (“CCI”) entrusted with the job of maintaining healthy competition and curbing abuse of monopoly in the market…